SC-58125 is a potent, selective inhibitor of COX-2 with IC50 of 0.05 uM, without inhibition on COX-1 (IC50>10 uM).
SC-58125 inhibited edema at the inflammatory site and was analgesic but had no effect on PG production in the stomach and did not cause gastric toxicity.
SC-58125 suppressed the inflammatory reaction and caused a marked decrease in the level of PGE2 but not TXB2 and 6-keto-PGF 1 alpha.
SC-58125 rapidly reversed paw edema and reduced the level of PGE2 in paw tissue to baseline, also reduced the expression of COX-2 mRNA and protein in the paw.
